Evidence map›Paper›PMID 40504161›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2025

Defining CDK12 as a tumor suppressor and therapeutic target in mouse models of tubo-ovarian high-grade serous carcinoma.

Jean Ching-Yi Tien, Yali Zhai, Rong Wu, Yuping Zhang, Yu Chang, Yunhui Cheng, Abigail J Todd, Christina E Wheeler, Shuqin Li, Rahul Mannan and 21 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Trial
  2. Review
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

31 authors.

Jean Ching-Yi TienMichigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI 48109.ORCID 0000-0002-2684-4450
Yali ZhaiDepartment of Pathology, University of Michigan, Ann Arbor, MI 48109.
Rong WuDepartment of Pathology, University of Michigan, Ann Arbor, MI 48109.
Yuping ZhangMichigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI 48109.ORCID 0000-0002-8727-5183
Yu ChangMichigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI 48109.
Yunhui ChengMichigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI 48109.
Abigail J ToddMichigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI 48109.
Christina E WheelerMichigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI 48109.
Shuqin LiMichigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI 48109.
Rahul MannanMichigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI 48109.ORCID 0000-0002-6642-0468
Caleb ChengMichigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI 48109.ORCID 0000-0003-1872-2661
Brian MagnusonMichigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI 48109.
Gabriel CruzMichigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI 48109.
Yizhi CaoMichigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI 48109.
Somnath MahapatraMichigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI 48109.
Carmine StolfiDepartment of Internal Medicine, University of Michigan, Ann Arbor, MI 48109.
Xuhong CaoMichigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI 48109.
Fengyun SuMichigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI 48109.
Rui WangMichigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI 48109.ORCID 0000-0002-5356-9685
Jianzhang YangState Key Laboratory of Chemical Biology, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, Shanghai 200032, People's Republic of China.
Licheng ZhouState Key Laboratory of Chemical Biology, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, Shanghai 200032, People's Republic of China.
Yuanyuan QiaoMichigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI 48109.ORCID 0000-0002-1178-3480
Lanbo XiaoMichigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI 48109.
Marcin CieslikMichigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI 48109.
Xiaoju WangMichigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI 48109.
Zhen WangState Key Laboratory of Chemical Biology, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, Shanghai 200032, People's Republic of China.ORCID 0000-0001-8762-6089
Jonathan ChouHelen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA 94115.ORCID 0000-0003-1258-0391
Eric R FearonDepartment of Pathology, University of Michigan, Ann Arbor, MI 48109.
Ke DingState Key Laboratory of Chemical Biology, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, Shanghai 200032, People's Republic of China.ORCID 0000-0001-9016-812X
Kathleen R ChoDepartment of Pathology, University of Michigan, Ann Arbor, MI 48109.
Arul M ChinnaiyanMichigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI 48109.ORCID 0000-0001-9282-3415

Funding

MICHIGAN MEDICAL SCIENTIST TRAINING PROGRAMT32GM007863 · NIGMS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI COLLINS, KATHLEEN L. · 1985 to 2024
$38.3M
Tissue/InformaticsP50CA186786 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Lakshmi Priya Kunju · 2014 to 2026
$27.6M
Exploring Precision Oncology: From Gene Fusions to lncRNAsR35CA231996 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI CHINNAIYAN, ARUL M · 2018 to 2024
$6.4M
Michigan-VUMC Biomarker Characterization CenterU2CCA271854 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Jeffrey John Tosoian · 2022 to 2026
$5.4M
Cellular and Molecular Biology at MichiganT32GM145470 · NIGMS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI John Chadwick Brenner · 2022 to 2026
$4.1M
Targeting the lipid kinase PIKfyve in pancreatic ductal adenocarcinomaF30CA288093 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Caleb Cheng · 2025 to 2026
$87k
HHS | NIH | National Cancer Institute (NCI) P50-CA186786HHS | NIH | National Cancer Institute (NCI) R35-CA231996HHS | NIH | National Cancer Institute (NCI) U2C-CA271854MOST | National Natural Science Foundation of China (NSFC) 22037003NCI NIH HHS F30 CA288093NCI NIH HHS P50 CA186786NCI NIH HHS R35 CA231996NCI NIH HHS U2C CA271854NIGMS NIH HHS T32 GM007863NIGMS NIH HHS T32 GM145470U.S. Department of Defense (DOD) W81XWH-21-1-0458
6 · The paper itself

Abstract

Ovarian cancer is the sixth leading cause of cancer death among American women, with most fatalities attributable to tubo-ovarian high-grade serous carcinoma (HGSC). This malignancy usually develops resistance to conventional chemotherapy, underscoring the need for robust preclinical models to guide the development of novel therapies. Here, we introduce an HGSC mouse model generated via

Indexed as

Cyclin-Dependent KinasesCystadenocarcinoma, SerousOvarian NeoplasmsAnimalsCell Line, TumorCRISPR-Cas SystemsDisease Models, AnimalFemaleHumansMiceMice, KnockoutTumor Suppressor Protein p53CDK12 protein, humanCyclin-Dependent KinasesTrp53 protein, mouseTumor Suppressor Protein p53CDK12CDK12/13 degradergenetically engineered mouse models (GEMMs)ovarian cancer

Identifiers

PMID40504161
PMCPMC12184368

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.